Read more stories about
Montana Biotech >>

MATR Sponsor:

MATR Supporters:

In search of a cure: Upstart Missoula biotech company Inimmune on the cutting edge of science

August 28, 2016View for printing

In a collection of small laboratories filled with glass beakers, liquid compounds and deep freezers, scientists with the upstart Missoula biotech firm Inimmune are looking to cure allergies, infectious diseases and cancer.

With a strong portfolio of drug candidates and a seasoned team of chemists, the scientists with Inimmune like their chances of getting a new drug to clinical trial within the next five years.

"Ideally, in 10 years we'll have one or more products possibly in Phase 3 clinical trials," said Jay Evans, president and CEO of Inimmune. "In an ideal world, we'll be on the doorstep of launching a potential cure for either food or seasonal allergies that could be life changing to lots of people."

"We have team members who had been there for over 20 years," said Evans. "The last thing we wanted to do was uproot their families and move them to Maryland. We began exploring options with GSK and devised a plan where we could start a company here in Missoula with the assistance of GSK."

"The potential is huge," Evans said. "When you talk about markets like allergy and autoimmunity, really the the sky's the limit. Hopefully ours will be a model for university professors and others to start a biotech here in Montana. It’s a great place to live and do that kind of work."

By Martin Kidston

Full Story: ... ge-science/
No reader comments so far. Be the first to comment by clicking the button below.

Reprinted under the Fair Use doctrine of international copyright law. Full copyright retained by the original publication. In accordance with Title 17 U.S.C. Section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.

E-mail this page to a friend!